Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers.

Cancer genetics - 1 Sept 2016

Leedom Tracey P, LaDuca Holly, McFarland Rachel, Li Shuwei, Dolinsky Jill S, Chao Elizabeth C

Abstract excerpt

CHEK2 mutations are associated with increased cancer risks, including breast; however, published risk estimates are limited to those conferred by CHEK2 founder mutations, presenting uncertainty in risk assessment for carriers of other CHEK2 mutations. This study aimed to assess phenotypes and molecular characteristics of CHEK2 mutation carriers (CHEK2 + s) from a multi-gene panel testing (MGPT) cohort, focusing...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Checkpoint Kinase 2

Share to Founder Effect

Share to CHEK2 gene

Share to Genetic factors in colorectal cancer

Share to Genetic Predisposition to Disease

Share to Genomics and Rare Diseases

Source

Identifiers

PMID: 27751358
DOI: 10.1016/j.cancergen.2016.08.005

Genes

CHEK2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Breast cancer risk is similar for CHEK2 founder and non-founder mutation carriers.PMID 27751358Read ↗

Differences in cancer prevalence among CHEK2 carriers identified via multi-gene panel testing.Semantic proximity Read ↗

Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).Semantic proximity Read ↗

Differences in Cancer Phenotypes Among Frequent CHEK2 Variants and Implications for Clinical Care-Checking CHEK2.Semantic proximity Read ↗

Breast and colorectal cancer risks among over 6,000 CHEK2 pathogenic variant carriers: A comparison of missense versus truncating variants.Semantic proximity Read ↗

Breast cancer risk associated with CHEK2 mutations.Semantic proximity Read ↗

The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2.Semantic proximity Read ↗

High risk of breast cancer in women with biallelic pathogenic variants in CHEK2.Semantic proximity Read ↗

Skin cancer risk in CHEK2 mutation carriers.Semantic proximity Read ↗

Genomic ascertainment of<i>CHEK2</i>-related cancer predispositionSemantic proximity Read ↗

Double CHEK2 Pathogenic and Low-Risk Variants and Associated Cancer Phenotypes.Semantic proximity Read ↗

A CHEK2 Genetic Variant Contributing to a Substantial Fraction of Familial Breast CancerSemantic proximity Read ↗

Identification of CHEK2 Germline Mutations in BRCA1/2- and PALB2-Negative Breast and Ovarian Cancer Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.